SG10201909638UA - Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules - Google Patents
Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii moleculesInfo
- Publication number
- SG10201909638UA SG10201909638UA SG10201909638UA SG10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA
- Authority
- SG
- Singapore
- Prior art keywords
- genetically modified
- mhc
- molecules
- major histocompatibility
- histocompatibility complex
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title abstract 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title abstract 5
- 241000699670 Mus sp. Species 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) II MOLECULES The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II and polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided. [No Figure]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552584P | 2011-10-28 | 2011-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201909638UA true SG10201909638UA (en) | 2019-11-28 |
Family
ID=47430036
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510056SA SG10201510056SA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
SG10201909638U SG10201909638UA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
SG11201400938UA SG11201400938UA (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510056SA SG10201510056SA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400938UA SG11201400938UA (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Country Status (25)
Country | Link |
---|---|
US (6) | US8847005B2 (en) |
EP (4) | EP2770822B9 (en) |
JP (2) | JP6285361B2 (en) |
KR (2) | KR101926442B1 (en) |
CN (3) | CN108401986B (en) |
AU (4) | AU2012327205B2 (en) |
BR (1) | BR112014009941B1 (en) |
CA (1) | CA2852962C (en) |
CY (2) | CY1119283T1 (en) |
DK (3) | DK2770822T3 (en) |
ES (3) | ES2914374T3 (en) |
HK (2) | HK1196999A1 (en) |
HR (3) | HRP20220616T1 (en) |
HU (2) | HUE034374T2 (en) |
IL (3) | IL231895B (en) |
IN (1) | IN2014CN03892A (en) |
LT (3) | LT2770822T (en) |
MX (1) | MX355726B (en) |
PL (3) | PL2770822T3 (en) |
PT (3) | PT3590332T (en) |
RS (3) | RS63220B1 (en) |
RU (1) | RU2660564C2 (en) |
SG (3) | SG10201510056SA (en) |
SI (3) | SI2770822T1 (en) |
WO (1) | WO2013063340A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
KR101926442B1 (en) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
EP2818478B1 (en) | 2011-10-28 | 2017-02-01 | Regeneron Pharmaceuticals, Inc. | Humanized IL-6 and IL-6 receptor |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
SI2958937T1 (en) * | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
CN105208855B (en) * | 2013-03-11 | 2018-04-27 | 瑞泽恩制药公司 | The transgenic mice of chimeric major histocompatibility complex (MHC) the II quasi-molecules of expression |
IL297607B2 (en) | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non–human animals having a humanized signal–regulatory protein gene |
KR102376041B1 (en) * | 2013-10-15 | 2022-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized il-15 animals |
SG11201604886WA (en) | 2014-04-08 | 2016-07-28 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors |
NO2785538T3 (en) | 2014-05-07 | 2018-08-04 | ||
EP3157956B1 (en) * | 2014-06-19 | 2020-02-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
LT3689140T (en) | 2014-11-24 | 2022-08-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
FI3850946T3 (en) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Non-human animals having a humanized cluster of differentiation 47 gene |
AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
MX2018005389A (en) | 2015-11-20 | 2018-09-05 | Regeneron Pharma | Non-human animals having a humanized lymphocyte-activation gene 3. |
EP3411392B1 (en) * | 2016-02-04 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
CN109068621B (en) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | Rodent with humanized TMPRSS gene |
CN116458475A (en) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | Non-human animals expressing exogenous terminal deoxynucleotidyl transferase |
JP7361031B2 (en) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Non-human animals containing a humanized TRKB locus |
WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
KR20210004994A (en) | 2018-03-26 | 2021-01-13 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized rodents to test therapeutic agents |
KR20210031868A (en) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animal model of DITRA disease and uses thereof |
CA3155234A1 (en) * | 2019-10-22 | 2021-04-29 | Megan Sykes | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice |
JP2023504172A (en) | 2019-12-02 | 2023-02-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Peptide-MHC II protein constructs and their uses |
BR112023018874A2 (en) | 2021-03-31 | 2023-10-03 | Regeneron Pharma | GENETICALLY MODIFIED MICE COMPRISING COMPONENTS OF THE HUMANIZED CELLULAR IMMUNE SYSTEM WITH IMPROVED DIVERSITY OF THE TCRB REPERTORY |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0437576B1 (en) | 1989-07-25 | 2002-07-03 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
ES2301183T3 (en) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER. |
AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
CA2325721A1 (en) * | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
WO2002000933A2 (en) | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
FR2827302B1 (en) * | 2001-07-13 | 2003-10-10 | Genoway | TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF |
US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
DE10347710B4 (en) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
JP4857450B2 (en) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | Transgenic non-human mammal that reproduces the pathology of human rheumatoid arthritis |
PT1802193E (en) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Method for generating a mouse homozygous for a genetic modification |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
NO347649B1 (en) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use. |
US20090271884A1 (en) | 2008-03-07 | 2009-10-29 | Regeneron Pharmaceuticals, Inc. | ES Cell-Derived Mice From Diploid Host Embryo Injection |
US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
DK3241435T3 (en) | 2009-07-08 | 2021-08-23 | Kymab Ltd | ANIMAL MODELS AND THERAPEUTIC MOLECULES |
CN101695587B (en) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | Method for preparing endothelial progenitor cell capturing bracket for gene modification and regulation |
BR112013000985A2 (en) | 2010-07-15 | 2017-09-05 | Technion Res & Dev Foundation | ISOLATED HIGH AFFINITY ENTITIES WITH T-CELL RECEPTOR SPECIFICITY WITH RESPECT TO NATIVE MHC CLASS II COMPLEXES AND AUTOANTIGENIC GLUTAMIC ACID DECARBOXYLASE (GAD) PEPTIDES |
US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
KR101926442B1 (en) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
SI2958937T1 (en) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
CN105208855B (en) | 2013-03-11 | 2018-04-27 | 瑞泽恩制药公司 | The transgenic mice of chimeric major histocompatibility complex (MHC) the II quasi-molecules of expression |
AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/en active IP Right Grant
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/en unknown
- 2012-10-26 PL PL12806199T patent/PL2770822T3/en unknown
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/en unknown
- 2012-10-26 SI SI201231056T patent/SI2770822T1/en unknown
- 2012-10-26 RS RS20220473A patent/RS63220B1/en unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/en active Active
- 2012-10-26 SI SI201231999T patent/SI3590332T1/en unknown
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/en active IP Right Grant
- 2012-10-26 PT PT191895333T patent/PT3590332T/en unknown
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/en active
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/en unknown
- 2012-10-26 ES ES19189533T patent/ES2914374T3/en active Active
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/en active Active
- 2012-10-26 MX MX2014004896A patent/MX355726B/en active IP Right Grant
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/en active Active
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en active Application Filing
- 2012-10-26 SI SI201231738T patent/SI3272214T1/en unknown
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/en active Active
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/en active Pending
- 2012-10-26 PL PL19189533T patent/PL3590332T3/en unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/en unknown
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/en active
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 PT PT128061991T patent/PT2770822T/en unknown
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/en unknown
- 2012-10-26 RS RS20170897A patent/RS56330B1/en unknown
- 2012-10-26 RS RS20200224A patent/RS59997B1/en unknown
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/en active IP Right Grant
- 2012-10-26 EP EP22152099.2A patent/EP4052572A1/en active Pending
- 2012-10-26 PL PL17171524T patent/PL3272214T3/en unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/en active
- 2012-10-26 ES ES17171524T patent/ES2774488T3/en active Active
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/en unknown
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
- 2014-10-23 HK HK14110588.1A patent/HK1196999A1/en unknown
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/en active Active
- 2017-09-04 HR HRP20171327TT patent/HRP20171327T1/en unknown
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/en unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
- 2018-07-24 HK HK18109591.4A patent/HK1250131A1/en unknown
-
2019
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/en unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/en unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201909638UA (en) | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules | |
MY178723A (en) | Genetically modified major histocompatibility complex mice | |
CY1121979T1 (en) | MICE EXPRESSING HUMANIZED T-LYMPHO CELL CO-RECEPTORS | |
CY1121223T1 (en) | Mice EXPRESSING A HUMANIZED MAJOR COMPLIANCE COMPLEX | |
EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
MX2017006802A (en) | Non-human animals expressing humanized cd3 complex. | |
PH12016500342A1 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
MX2020007021A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor. | |
MX2016008076A (en) | Human mesothelin chimeric antigen receptors and uses thereof. | |
AU2013312359A8 (en) | Genetically modified non-human animals and methods of use thereof | |
MY175954A (en) | Light-sensitive ion-passing molecules | |
MX353134B (en) | Genetically modified t cell receptor mice. | |
MX2014015679A (en) | Humanized il-7 rodents. | |
MX2021000586A (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules. |